Cargando…

COVD-23. PLANNED-USE GLUCARPIDASE FOR OUTPATIENT HIGH DOSE METHOTREXATE (HD-MTX) ADMINISTRATION IN PATIENTS WITH CNS LYMPHOMA (CNSL) DURING THE COVID-19 PANDEMIC

Infection with SARS CoV-2 virus has resulted in a global pandemic of COVID-19, a respiratory illness with a crude mortality rate of 3–4%. Risk of death is higher in the elderly and in patients with underlying comorbid conditions. When local incidence of COVID-19 is high, hospital resources are scarc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schaff, Lauren, Lobbous, Mina, Bozza, Alexis, Carlow, Dean, Nabors, Louis, Grommes, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Covid-19 and Neuro-Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650456/ http://dx.doi.org/10.1093/neuonc/noaa215.105

Ejemplares similares

PB2136: PLANNED-USE GLUCARPIDASE FOR OUTPATIENT HIGH DOSE METHOTREXATE (HD-MTX) ADMINISTRATION IN PATIENTS WITH CNS LYMPHOMA (CNSL) DURING THE COVID-19 PANDEMIC
por: Schaff, L., et al.
Publicado: (2022)

Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study
por: Schaff, Lauren R., et al.
Publicado: (2022)

COVD-03. IMPACT OF COVID-19 ON THERAPY PROVISION FOR CHILDREN WITH CNS TUMOURS
por: Hartley, Helen, et al.
Publicado: (2020)

COVD-01. VINBLASTINE MONOTHERAPY INDUCTION FOR LOCALISED CNS GERMINOMA DURING THE COVID-19 PANDEMIC
por: Moleron, Rafael, et al.
Publicado: (2020)

COVD-27. THE COVID-19 PANDEMIC AND NEURO-ONCOLOGICAL PATIENTS
por: Norman, Sofya, et al.
Publicado: (2020)

COVD-06. BRAIN TUMOURS AND COVID-19: THE PATIENT AND CAREGIVER EXPERIENCE
por: Voisin, Mathew, et al.
Publicado: (2020)

COVD-12. THE LONGITUDINAL IMPACT OF COVID-19 PANDEMIC ON NEUROSURGICAL PRACTICE
por: Alatar, Abdullah, et al.
Publicado: (2020)

COVD-30. A SNAPSHOT OF THE IMPACT OF COVID-19 ON PATIENTS WITH NERVOUS SYSTEM TUMORS
por: Aaroe, Ashley, et al.
Publicado: (2020)

COVD-02. ADAPTING RNA-NANOPARTICLE VACCINES FROM GLIOBLASTOMA TO SARS-COV-2
por: Mendez-Gomez, Hector, et al.
Publicado: (2020)

COVD-25. THE PARADOXICAL EFFECTS OF COVID-19 ON CANCER CARE IN THE NEURO-ONCOLOGY SETTING
por: Cort, Nicole, et al.
Publicado: (2020)

COVD-31. THE STATE OF NEURO-ONCOLOGY DURING THE COVID-19 PANDEMIC: A WORLDWIDE ASSESSMENT
por: Mrugala, Maciej, et al.
Publicado: (2020)

COVD-09. INVESTIGATION AND SUMMARY OF DIAGNOSIS AND TREATMENT OF NEUROLOGICAL TUMORS DURING COVID-19 IN CHINA
por: Liang, Zhen, et al.
Publicado: (2020)

COVD-03. ASSESSING THE IMPACT OF CORONAVIRUS 19 PANDEMIC ON NEURO-ONCOLOGY AT GUY’S CANCER CENTRE LONDON
por: Little, Jessica, et al.
Publicado: (2020)

COVD-07. THE IMPACT OF COVID-19 ON PATIENTS AND CAREGIVERS AFFECTED BY BRAIN TUMORS: THE PATIENT NAVIGATOR PERSPECTIVE
por: Walsh, Kyle
Publicado: (2020)

COVD-20. COVID-19 INFECTION DURING CHEMOTHERAPY FOR MALIGNANT GLIOMA: OUTCOMES AMONG 3 PATIENTS
por: Kim, Esther, et al.
Publicado: (2020)

COVD-29. CONTINUATION OF TEMOZOLOMIDE CHEMOTHERAPY IN A GLIOBLASTOMA PATIENT AFTER RESOLUTION OF COVID-19 PNEUMONIA
por: Thakkar, Jigisha, et al.
Publicado: (2020)

COVD-22. COVID-19+ GLIOMA PATIENT CARE: LESSONS FROM A 5-PATIENT CASE SERIES
por: Daher, Ahmad
Publicado: (2020)

COVD-01. ADAPTATION OF A GAMMA KNIFE ICON STEREOTACTIC RADIOSURGERY PROGRAM IN THE FACE OF A GLOBAL PANDEMIC
por: Wegner, Rodney, et al.
Publicado: (2020)

COVD-13. EFFECTS OF COVID-19 PANDEMIC ON NEUROSURGICAL ONCOLOGY PRACTICES AT INOVA HEALTH SYSTEM: AN INSTITUTIONAL EXPERIENCE
por: Dang, Danielle, et al.
Publicado: (2020)

COVD-08. THE DIVIDED PRINCIPLE OF JUSTICE: ETHICAL DECISION-MAKING IN CANCER CARE DURING THE COVID-19 PANDEMIC
por: Brenna, Connor, et al.
Publicado: (2020)

COVD-16. THE COVID-19 PANDEMIC FROM A NEURO-ONCOLOGY PERSPECTIVE: STRATEGIES, PROTOCOLS, AND LESSON LEARNED
por: Burke, John, et al.
Publicado: (2020)

COVD-19. COGNITION, CANCER, AND COVID: DELIVERING DIRECT-TO-HOME TELE-NEUROPSYCHOLOGY SERVICES TO NEURO-ONCOLOGY PATIENTS
por: Gardner, Melissa, et al.
Publicado: (2020)

COVD-17. TUMOR TREATING FIELDS FOR GLIOBLASTOMA THERAPY DURING THE COVID-19 PANDEMIC: EXPERT CONSENSUS ON USE AND EXPERIENCE
por: Tosha Gatson, Na, et al.
Publicado: (2020)

COVD-18. POTENTIAL TO HARNESS SARS-COV-2 NEUROTROPISM IN THE DELIVERY OF ONCOLYTIC VIROTHERAPY FOR THE TREATMENT OF HIGH-GRADE GLIOMA
por: Immidisetti, Amanda, et al.
Publicado: (2020)

COVD-15. COVIDNEUROONC: A UK MULTI-CENTRE, PROSPECTIVE COHORT STUDY OF THE IMPACT OF THE COVID-19 PANDEMIC ON THE NEURO-ONCOLOGY SERVICE
por: Fountain, Daniel, et al.
Publicado: (2020)

COVD-11. THE BRAIN TUMOR AND NOT FOR PROFIT AND CHARITY EXPERIENCE OF COVID 19: REACTING AND ADJUSTING TO AN UNPRECEDENTED GLOBAL PANDEMIC IN THE 21ST CENTURY
por: Ellen Maher, Mary, et al.
Publicado: (2020)

COVD-26. TELEPHONE CONSULTATIONS IN NEURO-ONCOLOGY DURING THE COVID-19 PANDEMIC: LEVELS OF PATIENT SATISFACTION AND COMPARISON WITH TRADITIONAL FACE-TO-FACE CONSULTATIONS
por: Toman, Emma, et al.
Publicado: (2020)

COVD-14. TELEMEDICINE REVIEW IN NEURO-ONCOLOGY: COMPARATIVE EXPERIENTIAL ANALYSIS FOR BARROW NEUROLOGICAL INSTITUTE AND GEISINGER HEALTH DURING THE 2020 COVID-19 PANDEMIC
por: Fonkem, Ekokobe, et al.
Publicado: (2020)

COVD-04. REAL-WORLD PERSPECTIVES: TUMOR TREATING FIELDS (TTFIELDS) UTILITY TO OPTIMIZE TREATMENT OF PATIENTS WITH GLIOBLASTOMA (GBM) AMIDST COVID-19 PANDEMIC
por: Frongillo, Peggy, et al.
Publicado: (2020)

COVD-28. IMPACT OF COVID‐19 IN CHILDHOOD CENTRAL NERVOUS SYSTEM TUMORS IN ARGENTINA. REPORT FROM THE NATIONAL PEDIATRIC CANCER REGISTRY, ROHA NETWORK
por: Baroni, Lorena, et al.
Publicado: (2020)

COVD-04. CHARACTERISTICS OF SARS-COV-2 IN 64 CHILDREN WITH CNS TUMORS: A REPORT FROM THE SIOP/ST. JUDE CHILDREN’S RESEARCH HOSPITAL (SJCRH) GLOBAL COVID-19 CHILDHOOD CANCER REGISTRY
por: Moreira, Daniel, et al.
Publicado: (2020)

COVD-02. COVID-19 AND CHILDHOOD CANCER CARE - THEMATIC ANALYSIS OF PUBLISHED SCIENTIFIC AND CLINICAL LITERATURE
por: Barton, Chris
Publicado: (2020)

Implementation of an Outpatient HD-MTX Initiative
por: Sokol, Kelsey, et al.
Publicado: (2022)

Glucarpidase to combat toxic levels of methotrexate in patients
por: Green, Jacalyn M
Publicado: (2012)

PB2106: REDUCTION OF METHOTREXATE (MTX) LEVELS AFTER GLUCARPIDASE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT RISK OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT WHO RECEIVE HDMTX: PHASE 2
por: De La Fuente, A., et al.
Publicado: (2022)

LPTO-01. LEPTOMENINGEAL METASTASIS FROM OVARIAN CARCINOMA TREATED WITH SYSTEMIC HIGH-DOSE METHOTREXATE
por: Coffee, Elizabeth, et al.
Publicado: (2019)

Methotrexate toxicity treated with continuous venovenous hemofiltration, leucovorin and glucarpidase
por: Connors, Nicholas J., et al.
Publicado: (2014)

Relationship Between the Free and Total Methotrexate Plasma Concentration in Children and Application to Predict the Toxicity of HD-MTX
por: Dong, Wei-Chong, et al.
Publicado: (2021)

ML-13 AN ATTEMPT OF RECHALLENGE OF HD-MTX AND MAINTENANCE THERAPY OF MTX FOR PATIENTS WITH PCNSL
por: Yamaguchi, Takashi, et al.
Publicado: (2019)

Treatment of methotrexate (MTX) intolerance: behavioural therapy, versus switch to parenteral MTX versus oral MTX
por: Verkaaik, M, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_t9bpt0verofiu5sjmdvsl5gcio